![Page 1: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/1.jpg)
Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive Disease Center Professor and Chief, Gastroenterology Vincent & Anna Kong Endowed Chair, GI Endoscopic Oncology University of California, Irvine
![Page 2: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/2.jpg)
Pancreatic Cystic Neoplasms: Still a clinical challenge
CEA? Amylase?
Cytology?
Biomarkers?
SCA MCN IPMN SPN
Imaging?
Size? Histology?
![Page 3: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/3.jpg)
![Page 4: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/4.jpg)
Pancreatic Cystic Neoplasms – Risk of Cancer
Subtype Risk of Malignancy
Main Duct (MD-IPMN) 36-68%
Mixed (Mixed-IPMN) 38-65%
Branch (BD-IPMN) 12-47%
Mucinous Cystic
Neoplasm (MCN) 10-17%
Solid Pseudopapillary
Neoplasm (SPN) 8-20%
Cystic Pancreatic
Neuroendocrine Tumor
(cPNET)
6-31%
![Page 5: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/5.jpg)
Sendai Consensus Guidelines
2004
Curr Gastroenterol Rep (2010) 12: 98-105
Risk Factors:
1. Size > 3cm
2. High risk features
Mural nodules
Dilated main PD (> 10mm)
Positive Cytology
![Page 6: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/6.jpg)
Lennon, AM; Canto, MI. Pancreas 2017;46: 745–750
![Page 7: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/7.jpg)
Basar O, Brugge WR. GIE 2018:85;5; 1032-1035
![Page 8: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/8.jpg)
Basar O, Brugge WR. GIE 2018:85;5; 1032-1035
![Page 9: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/9.jpg)
Vege S. Gastroenterology 2015;148:819–822
![Page 10: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/10.jpg)
”Fake” Guidelines ? Amsterdam – 115 resected patients1
AGA missed 12% of HGD/cancer
U. Penn – 239 resected patients2
AGA and Fukuoka missed 13% of HGD/cancer
Columbia, Yale, Jefferson – 269 resected patients3
AGA missed 93% of HGD/cancer
Texas, Brigham – 152 resected patients4
AGA and Fukuoka missed 25% and 18% of cancer
1. Lekkerkerker et al. GIE 2017;85:1025-31
2. Ma, G. et al. J Am Coll Surg 2016;223:729-737
3. Xu et al. Medicine (2017) 96:35
4. Lee et al. Endoscopy International Open 2017; 05: EE116–EE122
![Page 11: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/11.jpg)
Lekkerkerker et al. GIE 2017;85:1025-31
Suspected IPMN
![Page 12: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/12.jpg)
Lekkerkerker et al. GIE 2017;85:1025-31
![Page 13: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/13.jpg)
CONTACT Multi-center, 31 patients
100% specificity for serous cyst adenomas
0% 25% 50% 75% 100%
Napoléon B. Endoscopy 2015; 47: 26–32
![Page 14: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/14.jpg)
EUS nCLE: Serous Cystadenoma
![Page 15: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/15.jpg)
Ma, G. et al. J Am Coll Surg 2016;223:729-737
239 pts Resected
![Page 16: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/16.jpg)
Ma, G. et al. J Am Coll Surg 2016;223:729-737
AGA Fukuoka
Advanced Neoplasia (Ca, HGD) Missed by Guidelines
239 pts 239 pts
![Page 17: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/17.jpg)
Summary: Current Guidelines
Recent AGA guidelines are not superior to the
Fukuoka or European guidelines in identifying
advanced neoplasia (AN) in suspected PCNs
All guidelines have only fair PPV for detection of AN,
which would lead to avoidable resections in patients
without AN
Additionally, the high-risk features of all guidelines do
not accurately identify all patients with AN (↓NPV),
and can miss patients with AN
![Page 18: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/18.jpg)
Other Diagnostic Tools
Mucin examination - ”string sign”
Cyst fluid genetic testing
Through the needle (TTN)
endomicroscopy (nCLE)
TTN cystoscopy
TTN biopsy
![Page 19: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/19.jpg)
Singhi, A et al. Clin Cancer Res 2014;20:4381-4389
Aatur D. Singhi et al. Clin Cancer Res 2014;20:4381-4389
About 40%
of IPMN will
have GNAS
mutation
![Page 20: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/20.jpg)
The answer is on the wall…
IPMN
….but cytology alone is not good enough
![Page 21: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/21.jpg)
IPMN - 4 Histologic Sub-types
Yamaguchi, H. Modern Pathology 2007;20, 552–561
![Page 22: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/22.jpg)
IPMN – Subtyping by Mucin Stain
M. Distler 2014 BioMed Research International
![Page 23: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/23.jpg)
IPMN - 4 Histologic Sub-Types
Furukawa Gut 2011
Gastric (139)
Oncocytic (24)
Intestinal (101)
Pancreatico-
Biliary (19)
283 pts with IPMN
![Page 24: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/24.jpg)
X. Qi et al. European Journal of Internal Medicine 26 (2015) 652–657
19 Studies, 1954 pts
![Page 25: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/25.jpg)
X. Qi et al. European Journal of Internal Medicine 26 (2015) 652–657
![Page 26: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/26.jpg)
X. Qi et al. European Journal of Internal Medicine 26 (2015) 652–657
![Page 27: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/27.jpg)
nCLE - IPMN
Gastric Subtype
![Page 28: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/28.jpg)
IPMN – Gastric Subtype may have CEA
Yoon et al. Endoscopy 2014; 46: 1071–1077
![Page 29: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/29.jpg)
nCLE - IPMN
Oncocytic Subtype
![Page 30: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/30.jpg)
![Page 31: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/31.jpg)
EUS Through the Needle (TTN) Biopsy
![Page 32: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/32.jpg)
![Page 33: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/33.jpg)
![Page 34: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/34.jpg)
MUC2
![Page 35: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/35.jpg)
MUC5
![Page 36: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/36.jpg)
MUC6
![Page 37: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/37.jpg)
15 cystic lesions (mean 26.6mm)
Technical success was 87% (13/15).
1 AE: intra-cystic bleeding (self-limited)
No pancreatitis
EUS-guided TTNFB with histologic analysis yielded a
diagnosis in 11/15 patients (73%) vs 0/15 (0%) patients
using EUS-FNA and cytologic analysis (p < 0.01)
7 of 8 IPMNs were able to be subtyped based on histologic
analysis and MUC staining
Samarasena et al DDW 2018
![Page 38: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/38.jpg)
EUS-TTN Imaging & Biopsy
Fiberoptic Probe
nCLE
TTN forceps
![Page 39: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/39.jpg)
High Risk Stigmata
EUS-FNA ± nCLE ± TTN Bx c/w Serous Cystadenoma
Worrisome features: • Thicken wall • New mural
nodule • Rapid size • Family Hx CA • Suspicious
Cytology • Aggressive Sub-
type
No
(-) String Sign (-) CEA (-) Cytology (+) nCLE Vascular Network
Algorithm
Surgery Cyst > 1cm
Imaging Non-specific
Yes
No further work-up
c/w IPMN
c/w Mucinous Cystadenoma
Surgery
No Worrisome Features
EUS ± FNA in 6 mo Then alternate
MRCP/EUS q 1yr
Solitary cyst Distal Pancreas Female (+) String Sign (+) CEA (+) nCLE
• Jaundice • Enhancing Solid
component • Main PD ≥ 10mm
![Page 40: Pancreatic Cystic Neoplasms: Guidelines and beyond · Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive](https://reader030.vdocuments.us/reader030/viewer/2022040513/5e667d7a6becf51975018d2c/html5/thumbnails/40.jpg)
Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive Disease Center Professor and Chief, Gastroenterology Vincent & Anna Kong Endowed Chair, GI Endoscopic Oncology University of California, Irvine